PharmaCyte Biotech (PMCB) Notes Payables (2011 - 2015)

PharmaCyte Biotech (PMCB) posted quarterly Notes Payables of -$29746.0 for Q3 2015, down 185.39% quarter-over-quarter from $34834.0 in Q1 2014.

PharmaCyte Biotech (PMCB) Notes Payables (2011 - 2015) Analysis & Trends

PharmaCyte Biotech (PMCB) has reported Notes Payables for 5 consecutive years, with -$29746.0 the latest figure, recorded in Q3 2015.

In Q3 2015, Notes Payables changed N/A year-over-year to -$29746.0; the TTM figure through Jul 2015 stood at -$29746.0 (changed N/A YoY), while the FY2013 annual figure was $52259.0, changed N/A from the prior year.
Notes Payables eased to -$29746.0 in Q3 2015 per PMCB's latest filing, from $34834.0 in the prior quarter.
Across five years, Notes Payables topped out at $2.4 million in Q2 2011 and bottomed at -$29746.0 in Q3 2015.
Historically, Notes Payables has averaged $1.2 million across 5 years, with a median of $1.1 million in 2012.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.24 Bn	131.39 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	86.01 Bn	78.02 Bn	3.93 Bn
3	Argenx Se	65.61 Bn	60.42 Bn	1.37 Bn
4	Moderna	56.92 Bn	51.78 Bn	52.00 Mn
5	BeOne Medicines	42.17 Bn	37.07 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.27 Bn	992.69 Mn
7	BioNTech SE	27.77 Bn	9.38 Bn	668.28 Mn
8	Insmed	27.52 Bn	26.36 Bn	358.27 Mn
9	Royalty Pharma	27.36 Bn	26.52 Bn	-
10	PharmaCyte Biotech	4.48 Mn	4.48 Mn	-

Download Data